Your Health, We Care
In the pursuit of health and recovery, rational use of drugs is a crucial part. Patients should be fully aware of the information about the drug, including but not limited to efficacy, dosage, and contraindications, before using any drug. Be sure to follow the doctor's guidance and do not increase or decrease the dose or change the drug at will, so as not to affect the efficacy or cause adverse reactions; Be aware of drug-drug interactions and avoid self-medication.
Venetoclax is the world's first approved selective inhibitor of Bcl-2 that induces apoptosis in cancer cells by highly inhibiting Bcl-2 protein. It has a weak affinity for Bcl-···【more】
Article source：Captain MedicineRelease date：2024-08-14Recommended：298
Pemigatinib is a targeted therapy drug that is of great significance in the treatment of cholangiocarcinoma.Does Pemigatinib have side effects?Any medication can have some side eff···【more】
Article source：Captain MedicineRelease date：2024-08-14Recommended：258
Pemigatinibis primarily used for the treatment of adult patients with advanced, metastatic or unresectable cholangiocarcinoma who have received at least one prior systemic therapy ···【more】
Article source：Captain MedicineRelease date：2024-08-14Recommended：241
Pemigatinibhas demonstrated significant efficacy in the treatment of cholangiocarcinoma with FGFR2 fusion or rearrangement features, among other diseases.What are the side effects ···【more】
Article source：Captain MedicineRelease date：2024-08-14Recommended：277
Pemigatinib is used in adults to treat bile duct cancer that has spread to other parts of the body (metastatic) or cannot be removed with surgery.Is Pemigatinib good for cholangioc···【more】
Article source：Captain MedicineRelease date：2024-08-14Recommended：251
Pemigatinib is an effective treatment for advanced or metastatic cholangiocarcinoma caused by FGFR2 fusion or rearrangement.Is the treatment effect of Pemigatinib goodIn the FIGHT-···【more】
Article source：Captain MedicineRelease date：2024-08-14Recommended：235
Pemigatinib leads to constitutive activation of FGFR by activating FGFR amplification and fusion, thereby inhibiting FGFR1-3 phosphorylation and signaling and decreasing cell viabi···【more】
Article source：Captain MedicineRelease date：2024-08-14Recommended：245
Venetoclax is a targeted anti-cancer drug used to treat certain types of blood cancers, such as chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML). Venetoclax work···【more】
Article source：Captain MedicineRelease date：2024-08-13Recommended：297
Venetoclax is a novel oral small molecule drug that targets the BCL-2 protein to kill cancer cells by inducing the endogenous apoptotic pathway of tumor cells. In addition to AML, ···【more】
Article source：Captain MedicineRelease date：2024-08-13Recommended：387
Venetoclax is a small molecule drug that targets BCL-2 and is able to promote normal apoptosis of cancer cells by blocking the BCL-2 protein. Overexpression of BCL-2 protein in can···【more】
Article source：Captain MedicineRelease date：2024-08-13Recommended：278
Venetoclax is an oral anticancer drug targeting BCL-2 that promotes apoptosis of tumor cells by inhibiting the activity of BCL-2 protein. In China, venetoclax has been approved for···【more】
Article source：Captain MedicineRelease date：2024-08-13Recommended：216
By binding to BCL-2 protein, venetoclax inhibits the obstruction of apoptosis of tumor cells and effectively kills cancer cells. Venetoclax was approved by the NMPA in 2020 for the···【more】
Article source：Captain MedicineRelease date：2024-08-13Recommended：280
On November 21, 2025, the U.S. Food and Drug Administration (FDA) approved the regimen of pembrolizu···【more】
Recommended：1612025-17-12
Lung cancer is the most rapidly increasing malignant tumor with the fastest increasing morbidity and···【more】
Recommended：4002024-09-07
On December 12, 2025, the U.S. Food and Drug Administration (FDA) approved niraparib in combination ···【more】
Recommended：1552025-15-12
The U.S. Food and Drug Administration (FDA) announced today that it has approved Omisirge (omidubice···【more】
Recommended：1732025-10-12
On December 4, 2025, the U.S. Food and Drug Administration (FDA) approved lisocabtagene maraleucel (···【more】
Recommended：1542025-08-12
On December 3, 2025, the U.S. Food and Drug Administration (FDA) granted full approval to pirtobruti···【more】
Recommended：1882025-04-12
Primary analysis data from the randomized, double-blind, placebo-controlled phase III HER2CLIMB-02 s···【more】
Recommended：1692025-01-12
The Cure SMA Foundation, a global leading non-profit organization dedicated to spinal muscular atrop···【more】
Recommended：1652025-27-11
Lucius Pharmaceuticals (Lao) LTD. (Lucius Pharmaceuticals), with its manufacturing campus in Laos located in the capital city of Vientiane in 2020, officially begins its great journey to make effective and affordable medicines available to people in need around the world...More
Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address:No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Whatsapp:
